Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study

Masahiko Yamaguchi,1 Takeshi Nishijima,2 Jun Shimazaki,3 Etsuko Takamura,4 Norihiko Yokoi,5 Hitoshi Watanabe,6 Yuichi Ohashi1 1Department of Ophthalmology, Ehime University School of Medicine, Ehime, 2Department of Safety Vigilance Group, Santen Pharmaceutical Co., Ltd., Osaka, 3Department of Ophth...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yamaguchi M, Nishijima T, Shimazaki J, Takamura E, Yokoi N, Watanabe H, Ohashi Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/f61c014d2cc4446fbf1e2a040096416c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f61c014d2cc4446fbf1e2a040096416c
record_format dspace
spelling oai:doaj.org-article:f61c014d2cc4446fbf1e2a040096416c2021-12-02T05:44:03ZReal-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study1177-5483https://doaj.org/article/f61c014d2cc4446fbf1e2a040096416c2015-12-01T00:00:00Zhttps://www.dovepress.com/real-world-assessment-of-diquafosol-in-dry-eye-patients-with-risk-fact-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Masahiko Yamaguchi,1 Takeshi Nishijima,2 Jun Shimazaki,3 Etsuko Takamura,4 Norihiko Yokoi,5 Hitoshi Watanabe,6 Yuichi Ohashi1 1Department of Ophthalmology, Ehime University School of Medicine, Ehime, 2Department of Safety Vigilance Group, Santen Pharmaceutical Co., Ltd., Osaka, 3Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Chiba, 4Department of Ophthalmology, School of Medicine, Tokyo Women’s Medical University, Tokyo, 5Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, 6Department of Ophthalmology, Kansai Rosai Hospital, Hyogo, Japan Purpose: To evaluate the efficacy and safety of diquafosol (DQS) ophthalmic solution in dry eye (DE) patients wearing contact lenses (CLs) or with concomitant meibomian gland dysfunction (MGD) or conjunctivochalasis in a real-world setting. Patients and methods: From a cohort of patients enrolled in a prospective observational study, DE patients who met the Japanese diagnostic criteria and who received DQS as a monotherapy were extracted and stratified according to the presence or absence of CL use, MGD, and conjunctivochalasis. Corneal and conjunctival fluorescein staining score, tear film break-up time, total symptom score (12 DE-related subjective symptoms), patient-reported outcomes, and adverse reactions were investigated. Results: DQS treatment resulted in significant improvement in total symptom score, corneal and conjunctival fluorescein staining score, and tear film break-up time without significant differences between patient subgroups with versus without CL use, MGD, or conjunctivochalasis. Comparable proportions of patients perceived symptomatic improvements in all subgroups. There were no adverse reactions specifically associated with the CL use or any comorbidity of MGD or conjunctivochalasis. Conclusion: DQS can be used effectively and safely as a monotherapy for the treatment of DE patients wearing CLs or with concomitant MGD or conjunctivochalasis. Keywords: clinical practice, dry eye syndrome, patient-reported outcome, Diquas®Yamaguchi MNishijima TShimazaki JTakamura EYokoi NWatanabe HOhashi YDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 2251-2256 (2015)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Yamaguchi M
Nishijima T
Shimazaki J
Takamura E
Yokoi N
Watanabe H
Ohashi Y
Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
description Masahiko Yamaguchi,1 Takeshi Nishijima,2 Jun Shimazaki,3 Etsuko Takamura,4 Norihiko Yokoi,5 Hitoshi Watanabe,6 Yuichi Ohashi1 1Department of Ophthalmology, Ehime University School of Medicine, Ehime, 2Department of Safety Vigilance Group, Santen Pharmaceutical Co., Ltd., Osaka, 3Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Chiba, 4Department of Ophthalmology, School of Medicine, Tokyo Women’s Medical University, Tokyo, 5Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, 6Department of Ophthalmology, Kansai Rosai Hospital, Hyogo, Japan Purpose: To evaluate the efficacy and safety of diquafosol (DQS) ophthalmic solution in dry eye (DE) patients wearing contact lenses (CLs) or with concomitant meibomian gland dysfunction (MGD) or conjunctivochalasis in a real-world setting. Patients and methods: From a cohort of patients enrolled in a prospective observational study, DE patients who met the Japanese diagnostic criteria and who received DQS as a monotherapy were extracted and stratified according to the presence or absence of CL use, MGD, and conjunctivochalasis. Corneal and conjunctival fluorescein staining score, tear film break-up time, total symptom score (12 DE-related subjective symptoms), patient-reported outcomes, and adverse reactions were investigated. Results: DQS treatment resulted in significant improvement in total symptom score, corneal and conjunctival fluorescein staining score, and tear film break-up time without significant differences between patient subgroups with versus without CL use, MGD, or conjunctivochalasis. Comparable proportions of patients perceived symptomatic improvements in all subgroups. There were no adverse reactions specifically associated with the CL use or any comorbidity of MGD or conjunctivochalasis. Conclusion: DQS can be used effectively and safely as a monotherapy for the treatment of DE patients wearing CLs or with concomitant MGD or conjunctivochalasis. Keywords: clinical practice, dry eye syndrome, patient-reported outcome, Diquas®
format article
author Yamaguchi M
Nishijima T
Shimazaki J
Takamura E
Yokoi N
Watanabe H
Ohashi Y
author_facet Yamaguchi M
Nishijima T
Shimazaki J
Takamura E
Yokoi N
Watanabe H
Ohashi Y
author_sort Yamaguchi M
title Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
title_short Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
title_full Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
title_fullStr Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
title_full_unstemmed Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
title_sort real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/f61c014d2cc4446fbf1e2a040096416c
work_keys_str_mv AT yamaguchim realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
AT nishijimat realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
AT shimazakij realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
AT takamurae realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
AT yokoin realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
AT watanabeh realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
AT ohashiy realworldassessmentofdiquafosolindryeyepatientswithriskfactorssuchascontactlensmeibomianglanddysfunctionandconjunctivochalasissubgroupanalysisfromanbspprospectiveobservationalstudy
_version_ 1718400270226948096